Results 51 to 60 of about 2,131 (185)

Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

The Journal of Headache and Pain, 2021
Background Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical trials include
Stephen D. Silberstein, Joshua M. Cohen, Ronghua Yang, Sanjay K. Gandhi, Evelyn Du, Adelene E. Jann, Michael J. Marmura   +6 more
doaj   +1 more source

Longitudinal effects of CGRP‐targeting migraine therapies on blood pressure and body mass index: A 12‐month retrospective analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare blood pressure (BP) and body mass index (BMI) trajectories associated with individual calcitonin gene‐related peptide (CGRP)‐targeting migraine therapies versus matched CGRP‐unexposed controls. Background CGRP is a potent vasodilator with established roles in vascular homeostasis and metabolic regulation.
Phillip Phan, Scott Keith, Michael Li, Richard Hass, Wan‐Jen Hsieh, Michael Marmura, Hsiangkuo Yuan   +6 more
wiley   +1 more source

PND109 Improvements in Patient-Reported Migraine PAIN Intensity and Composite Migraine Symptoms with Fremanezumab in the Real World

, 2020
Objectives: Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) pathway, has been approved for migraine prevention in adults with episodic migraine (EM) or chronic migraine (CM).
Mauskop, A, McAllister, P, Dotiwala, Z, Casciano, J, Thompson, S, Cohen, J M, Lamerato, Lois, Krasenbaum, L, Tangirala, K   +8 more
core   +1 more source

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source

Comparative Clinical Efficacy Study between Erenumab and Fremanezumab

Medical Sciences Forum, 2022
A retrospective comparative study was conducted to compare the efficacy of monoclonal antibody drugs against the calcitonin gene-related peptide pathway in migraine and to establish whether they can be considered equivalent therapeutic alternatives for ...
Raquel Fresquet, Lucia Sopena, Jose Manuel Vinuesa, Aritz Merchan, Lucía Cazorla, Maria Perez, Alberto Frutos, Mercedes Arenere, Maria del Puerto Pardo, Maria de los Ángeles Allende, Tránsito Salvador   +10 more
doaj   +1 more source

Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma

Cureus, 2022
Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recurred despite surgical and chemo-radiological treatment.
Kawamura, Shin, Katsuki, Masahito, Kashiwagi, Kenta, Koh, Akihito   +3 more
openaire   +2 more sources

Fremanezumab for the Preventive Treatment of Migraine : Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response [PDF]

, 2021
To evaluate the efficacy of monthly or quarterly fremanezumab in patients with chronic migraine or episodic migraine and documented inadequate response to 2, 3, or 4 classes of prior migraine preventive medications.
Campos, Verena Ramirez, Pozo-Rosich, Patricia, Yang, Ronghua, Cohen, Joshua M., Ning, Xiaoping, Universitat Autònoma de Barcelona, Pazdera, Ladislav, Xiaoping Ning, Ronghua Yang, Verena Ramirez Campos, Patricia Pozo-Rosich, Ladislav Pazdera, Joshua M Cohen   +12 more
core   +1 more source

The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness [PDF]

Introduction: In 2020, the Italian Medicines Agency (AIFA) approved the reimbursement of calcitonin gene-related peptide (CGRP) pathway monoclonal antibodies (mAbs), including fremanezumab, in patients with a Migraine Disability Assessment Scale (MIDAS ...
Cepparulo, Mario, null, null, Sacco, Simona, Granato, Antonio, Benedetto, Chiara, Guerzoni, Simona, Rao, Renata, Sette, Giuliano, Bartolini, Marco, Brighina, Filippo, Geppetti, Pierangelo, Ambrosini, Anna, Vernieri, Fabrizio, Rainero, Innocenzo, Coppola, Gianluca, Bandettini, Monica, D'Onofrio, Florindo, Tassorelli, Cristina, Reggio, Ester, Sarchielli, Paola, Kokturk, Pinar, Barbanti, Piero, Messina, Stefano, Cevoli, Sabina, Iannacchero, Rosario, Gori, Sara, Perini, Francesco, Di Fiore, Paola, Valente, Mariarosaria, Finocchi, Cinzia, D’Onofrio, Florindo, Russo, Antonio, De Simone, Roberto, Usai, Susanna, Prudenzano, Maria Pia   +34 more
core   +3 more sources

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study

Frontiers in Neurology, 2023
BackgroundMedication-overuse headache is highly prevalent in tertiary care centers. It may be a cause or consequence of the overuse of symptomatic medications for migraine attacks.ObjectiveWe aimed to compare the efficacy of anti-CGRP monoclonal ...
Abouch V. Krymchantowski, Carla Jevoux, Ana Gabriela Krymchantowski, Raimundo Pereira Silva-Néto   +3 more
doaj   +1 more source

Framework for headache management in pediatric patients with stroke and cerebrovascular lesions: A narrative review

Headache: The Journal of Head and Face Pain, Volume 66, Issue 9, Page 2138-2155, October 2026.
Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland, Samuel J. Belfer, Christine K. Fox, Samantha L. Irwin, Rachel Vassar, Ann Oh, Sruthi Ilangovan, Amy A. Gelfand   +7 more
wiley   +1 more source